Table 3 Incidence of molecular marker immunopositivity in OSCC (Cohort III)
Biomarker | Total patients (n = 43) | Lymph node-positive (n = 16) | Lymph node-negative (n = 27) |
|---|---|---|---|
AZGP1 cytoplasmic | 31 (72%) | 12 (75%) | 19 (70%) |
AZGP1 nuclear | 25 (58%) | 11 (69%) | 14 (52%) |
BTG2 | 16 (37%) | 7 (44%) | 9 (33%) |
CBX2 | 33 (77%) | 15 (94%) | 18 (67%) |
CNTNAP2 | 6 (14%) | 4 (25%) | 2 (7%) |
NME5 | 12 (28%) | 6 (38%) | 6 (22%) |
S100A8 | 11 (26%) | 3 (19%) | 8 (30%) |
SCUBE2 | 12 (28%) | 1 (6%) | 11 (41%) |
SERPINA11 | 17 (40%) | 7 (44%) | 10 (37%) |
STC2 | 20 (47%) | 7 (44%) | 13 (48%) |
STK32B | 15 (35%) | 4 (25%) | 11 (41%) |
SUSD3 | 25 (58%) | 9 (56%) | 16 (59%) |
UBE2C | 8 (19%) | 3 (19%) | 5 (19%) |
WHSC1L1 | 37 (86%) | 14 (88%) | 23 (85%) |